[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Quovadis Associazione\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100590936","the-predictive-value-of-dobutamine-echo-stress-in-the-clinical-response-to-ccm-therapy-in-advanced-hf-100590936",false,"NCT06973902","The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF","Advanced Heart Failure: The Predictive Value of Dobutamine Echo-stress in the Clinical Response to Cardiac Contractility Modulation Therapy (CCM)","PREDICT-CCM","Inclusion Criteria:\n\n* Subject of both sexes with age ≥ 18 years,\n* Ability to understand and sign informed consent to participate in the study and consent to process sensitive personal data.\n* Carrier of symptomatic heart failure, despite optimal medical therapy (OMT),\n* Reduced left ventricular systolic function (E.F. \\\u003C50%),\n* It was positively evaluated for implanting a system for cardiac contractility modulation (CCM) (according to the European Society of Cardiology 2021 Guidelines on heart failure and the provisions of the C.E. mark approval)13.\n* Have presented at least one hospitalization, access to the Emergency Department, or access to day hospital facilities for more than 4 hours (e.g., by intravenous infusion of cardiac inotropic drugs) in the year before implantation\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 1 year due to non-cardiac comorbidities that reduce prognosis,\n* Presence of contraindications to the CCM implantation procedure (absence of vascular access usable for CCM implantation, active infectious processes, active severe coagulopathies, presence of mechanical tricuspid valve),\n* Contraindications to the performance of the echocardiographic test under pharmacological stress (heart failure in progress, myocardial infarction in the acute phase, acute inflammatory processes of the heart muscle and\u002For pericardium, critical aortic valve stenosis and severe obstructions to left ventricular outflow, dissecting aneurysm of the aorta, severe arrhythmias not controlled by therapy, known hypersensitivity to the drug, intraventricular thrombi).","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","The goal of this observational cohort study, which is both retrospective and prospective, is to evaluate the long-term clinical and instrumental response to Cardiac Contractility Modulation (CCM) treatment in adult subjects suffering from symptomatic heart failure (HF) due to systolic left ventricular dysfunction, despite adequate medical therapy. Based on the response to stress echocardiography with preimplantation low-dose Dobutamine, the main questions it aims to answer are:\n\n* What is the proportion of subjects who experience a clinical response to CCM therapy at 12 months (NYHA reduction ≥ 1 class)?\n* There was a reduction in the number of hospitalizations, visits to the Emergency Department, and access to day hospital facilities for more than 4 hours compared to the year before the study (e.g., by intravenous infusion of cardiac inotropic drugs)?\n* What is the estimated change in the quality-of-life score using the \"Quality of Life Questionnaire with Heart Failure - Minnesota\" (MLHFQ) between baseline and the end of follow-up?\n* What is the change in walking distance between baseline and the end of the follow-up in the walk test (6MWT) (optional)?\n* What is the difference in NT-proBNP levels between baseline and the end of follow-up? Participants are already receiving CCM support as part of their regular medical care for heart failure.",[25],"Symptomatic Congestive Heart Failure",[27,28,29,30],"Heart failure","systolic left ventricular dysfunction","low-dose dobutamine stress echocardiography","Cardiac Contractility Modulation (CCM)","RECRUITING","2025-07-24",{"date":34,"type":35},"2025-07-29","ACTUAL",{"date":37,"type":35},"2025-07-10",{"date":39,"type":21},"2028-12-31",{"name":41,"class":42},"Quovadis Associazione","OTHER",13,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100467459","physiological-ventricular-pacing-vs-managed-ventricular-pacing-for-persistent-af-prevention-in-prolonged-av-interval-100467459","NCT05367037","Physiological Ventricular Pacing Vs Managed Ventricular Pacing for Persistent AF Prevention in Prolonged AV Interval","Physiological Ventricular Pacing Versus Managed Ventricular Pacing for Persistent Atrial Fibrillation Prevention in Patients With Prolonged Atrioventricular Interval: a Multicenter RCT","PhysioVP-AF","Inclusion Criteria:\n\n18 years older patients, able to express Informed Consent, with prolonged atrioventricular interval (PR\\>180 ms) and one of the following indications for PM implantation according to current guidelines:\n\n* Sinus node disease.\n* Paroxysmal type1or 2 second-degree AV-block.\n\nExclusion Criteria:\n\n* Candidacy for implantable cardioverter-defibrillator or cardiac resynchronization therapy device implantation.\n* Severe grade mitral or aortic regurgitation\u002Fstenosis.\n* Atrial fibrillation ablation (left pulmonary veins).\n* Cardiac surgery \\\u003C 3 months before PM implantation.\n* History of long-standing persistent AF.\n* Permanent third-degree AV block.\n* Participation in another clinical trial in the past 3 months.\n* Pregnancy or intention to become pregnant.\n* Life expectancy of \\\u003C 3 years.",{"count":53,"type":21},640,"INTERVENTIONAL",[56],"NA","A multicenter, prospective, randomized study in a 1:1 ratio, single-blind with double-blind evaluation to evaluate the superiority of physiological ventricular pacing (proposed modality) vs. managed ventricular pacing (control) for prevention of persistent AF (PeAF) occurrence in patients with prolonged atrioventricular interval (PR≥180 ms) and indication for pacing: sinus node disease and\u002For paroxysmal type 1 or 2-second degree AV block.",[59,60],"Sinus Node Disease","Atrioventricular; Block, Second Degree (Types I and II)",[59,62,63,64],"Paroxysmal AV-block","conduction system pacing","persistent atrial fibrillation","2025-05-06",{"date":67,"type":35},"2025-05-11",{"date":69,"type":35},"2022-07-27",{"date":71,"type":21},"2028-12",{"name":41,"class":42},1,""]